Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
2
50%
Ph early_phase_1
1
25%
Ph phase_1
1
25%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (25.0%)
Phase 11 (25.0%)
Phase 22 (50.0%)

Trials by Status

completed375%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedearly_phase_1

Pexacerfont for Stress-induced Food Craving

NCT01656577
completedphase_2

Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^

NCT01227980
completedphase_2

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

NCT00481325
completedphase_1

Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder

NCT00135421

Clinical Trials (4)

Showing 4 of 4 trials
NCT01656577Early Phase 1

Pexacerfont for Stress-induced Food Craving

Terminated
NCT01227980Phase 2

Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^

Completed
NCT00481325Phase 2

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

Completed
NCT00135421Phase 1

Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4